BREAK IN TRANSCRIPT
Mr. WAXMAN. Mr. Speaker, I rise in support of H.R. 307, the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, and urge my colleagues to support this bill as well.
Mr. Speaker, this bill has been a long time coming. In fact, it's the same one we passed just last month at the end of the 112th Congress. H.R. 307 reflects a lengthy, but extremely productive process with our Senate colleagues and their staff to come together to bridge the differences between earlier House and Senate bills. H.R. 307 is the product of that effort. It is our hope that this time around, the Senate will pass the bill as soon as possible after the House acts on the legislation today.
Toward that end, H.R. 307 reauthorizes and makes minor--but important--improvements to various programs and activities first established in the 2002 Public Health Security and Bioterrorism Preparedness and Response Act; 2004 Project Bioshield Act; and the 2006 Pandemic and All-Hazards Preparedness Act, or as it is commonly referred to, ``PAHPA.'' These programs and activities are key in helping to ensure that our nation is well prepared to successfully manage the effects of natural disasters, infectious disease outbreaks, and acts of bioterrorism.
H.R. 307 includes dozens of changes to these underlying authorities. Let me highlight just three provisions that deserve special attention:
First, the bill will ensure that the Food and Drug Administration focuses on medical countermeasures of the highest importance. Medical countermeasures are products designed to combat chemical, biological, radiological, and nuclear agents. H.R. 307 will facilitate communication between the FDA and product sponsors--particularly on high priority countermeasures for which sponsors have developed regulatory management plans--to resolve scientific and regulatory questions and help make these products available more quickly. Just last month, FDA approved the first drug developed and procured under Project BioShield.
The FDA provisions in H.R. 307 will also facilitate the rapid provision of existing medicines to people in need during an emergency. Taken together, these FDA provisions--along with the renewed emphasis in our countermeasure enterprise through other parts of the legislation--will make it possible for a greater number of drugs and devices to move from early development to procurement.
Second, the legislation makes improvements to the nation's blueprint for public health preparedness and response activities that will enhance the ability of our diverse health care system to respond to mass casualty emergencies. Among such improvements are clarifying the role of the Assistant Secretary of Preparedness and Response as the lead office within the Department of Health and Human Services for emergency preparedness and response. H.R. 307 also establishes a new authority to permit the Secretary of the Department of Health and Human Services to approve a request of a state, territory, or an Indian tribe to redeploy certain federally-supported employees during the time of a national emergency to geographic areas where these employees are needed most.
Finally, H.R. 307 continues support for investments in state and local public health departments. Such investments are necessary to make certain that we have the requisite public health infrastructure in place to respond immediately and appropriately to any public health threat that may arise.
This legislation reflects the effort of a number of members--Democrats and Republicans alike. On our side of the aisle, Congressman Green, Congresswoman Eshoo, Congressman Markey, and our Health Subcommittee Ranking Member, Congressman Pallone, have been deeply involved. I want to thank them and their staff for all the long and incredibly hard work they have put into this legislation and to the process of getting us here today.
I urge my colleagues to vote in favor of H.R. 307.
BREAK IN TRANSCRIPT